Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Bausch + Lomb

Status and phase: Completed; Phase 3

Conditions: Cataract

Treatments: Drug: Placebo; Drug: Bromfenac

Study type: Interventional

Funder types: Industry

Identifiers

NCT00704418

CL-S&E-0415081-P-WR

Details and patient eligibility

About

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Enrollment: 156 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Scheduled for cataract surgery

Exclusion criteria

• Known hypersensitivity to bromfenac and salicylates

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

156 participants in 2 patient groups, including a placebo group

Bromfenac

Experimental group

Description:

Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily

Treatment:

Drug: Bromfenac

Placebo

Placebo Comparator group

Description:

Placebo, dosed 1 drop daily

Treatment:

Drug: Placebo